Risk stratification in patients with unstable angina and/or non-ST-elevation myocardial infarction by Troponin T and plasminogen-activator-inhibitor-1 (PAI-1)

Thromb Res. 2004;114(4):251-7. doi: 10.1016/j.thromres.2004.06.040.

Abstract

Background: Increased Troponin T (TnT) and PAI-1 levels are markers of poor outcome in acute coronary syndromes (ACS). In order to stratify the risk for 30-day combined endpoint of mortality and/or reinfarction in unstable angina and/or non-ST-elevation myocardial infarction (UA/NSTEMI), TnT and PAI-1 levels were simultaneously assessed.

Methods: The TnT and PAI-1 levels of 113 patients with UA/NSTEM were estimated within the first 48 h. Initial therapy was medical. Percutaneous coronary interventions were performed in case of recurrent ischemia and/or hemodynamic and/or rhythmic instability.

Results: Statistically significant differences in mean admission PAI-1 (4.2+/-3.4 vs. 2.8+/-2.4 U/ml, p<0.05), mean peak PAI-1 levels within the first 48 h (4.98 +/- 3.1 vs. 3.4 +/- 2.5 U/ml, p < 0.05), and no significant difference in any TnT level were observed between patients with and without 30-day mortality and/or reinfarction. The risk for 30-day mortality and/or reinfarction significantly increased in patients with admission PAI-1 levels > 4.0 U/ml (OR=4.44, 95%CI=1.47-13.4), peak PAI-1 levels > 4.0 U/ml (OR=5.78, 95%CI=1.838-18.20) and with simultaneously increased peak PAI-1 > 3.5 U/ml and TnT > 0.1 microg/l within the first 48 h (OR=4.9, 95%CI=1.569-15.385).

Conclusions: Simultaneous assessment of TnT and PAI-1 would provide complementary prognostic information and enable clinicians to stratify risk more effectively among patients with UA/NSTEMI.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Angina Pectoris / complications
  • Angina Pectoris / diagnosis*
  • Angina Pectoris / mortality
  • Biomarkers / blood
  • Electrocardiography
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction / complications
  • Myocardial Infarction / diagnosis*
  • Myocardial Infarction / mortality
  • Plasminogen Activator Inhibitor 1 / blood*
  • Predictive Value of Tests
  • Prognosis
  • Recurrence
  • Risk Assessment
  • Troponin T / blood*

Substances

  • Biomarkers
  • Plasminogen Activator Inhibitor 1
  • Troponin T